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Abstract 
Objective: Heterozygous inactivating mutations in GCK are associated with defects in 
pancreatic insulin secretion and/or hepatic glycogen synthesis leading to mild chronic 
hyperglycemia of maturity onset diabetes of young type 2 (MODY2). However, the effect of 
naturally occurring GCK mutations on the pathogenesis for MODY2 hyperglycemia remains 
largely unclear, especially in the Asian population. The aim of this study is to explore the 
potential pathogenicity of novel GCK mutations related to MODY2. 
Methods: Genetic screening for GCK mutations from 96 classical MODY families was 
performed, and structure-function characterization and clinical profile of identified GCK 
mutations were conducted.  
Results: Five novel (F195S, I211T, V222D, E236G and K458R) and five known (T49N, 
I159V, R186X, A188T and M381T) mutations were identified and co-segregated with 
hyperglycaemia in their pedigrees. R186X generates non-functional truncated form and 
V222D and E236G fully inactivate glucokinase due to severe structure disruptions. The other 
seven GCK mutations exhibited marked reductions in catalytic efficiency and 
thermo-stability; notably, the interaction with GKRP was significantly enhanced in I211T, 
I159V, T49N and K458R, reduced in F195S and M381T, and completely lost with A188T. 
31% (17/55) of MODY2 patients showed signs of insulin resistance. Conventional 
hypoglycemia treatment did not improve the HbA1C in MODY2 patients when insulin 
resistance is not present. 
Conclusions: Five novel GCK mutations have been identified in Chinese MODY. The 
defects in enzymatic activity and protein stability, together with alteration of GKRP binding 
on GCK mutants may synergistically contribute to the development of MODY2 
hyperglycaemia. No treatment should be prescribed to MODY2 patients when insulin 
resistance is not present. 
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Abbreviations 
GCK Glucokinase 
GKRP Glucokinase regulatory protein 
GSIS Glucose-stimulated insulin secretion 
G6P   Glucose-6-phosphate 
GKAs    Glucokinase activators 
MODY    Maturity-onset diabetes of the young 
mGCK mutant GCK 
OHA   Oral hypoglycaemic agents 
WT GCK wild-type GCK 
Y2H   Yeast two-hybrid 
 
1.    Introduction 
Glucokinase (GCK), specifically expressed in both the pancreatic β cells and hepatocytes, 
catalyzes the conversion of glucose to glucose-6-phosphate (G6P) [1]. In pancreatic β cells, 
GCK acts as a glucose sensor that determines glucose utilization, which is necessary for 
glucose-stimulated insulin secretion [2]. In hepatocytes, GCK determines the rate of both 
glucose uptake and glycogen synthesis and is essential for the regulation of various 
glucose-responsive genes [3]. Heterozygous inactivating mutations in GCK gene are 
associated with defects in pancreatic insulin secretion and/or hepatic glycogen synthesis 
leading to mild chronic hyperglycemia of maturity-onset diabetes of the young type 2 
(MODY2) or GCK-MODY [4]. MODY2 is characterized by mild, non-progressive 
hyperglycaemia from birth; these patients rarely present with diabetic complications and 
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usually do not require routine pharmacological treatment [5, 6]. The heterogeneity of 
MODY2 subtype distribution among different ethnic groups has also been implicated，
wherein the prevalence of MODY2 in Caucasian MODY cases is as high as 32–63% [4, 
7-10]. With the advancement in the understanding of MODY2 phenotypes [11] and molecular 
diagnosis techniques, more and more GCK mutations were detected in Asian MODY2 
patients [12, 13].  
Global homozygous GCK knockout mice result in perinatal death from severe diabetes 
[14]. Heterozygous null for GCK mice develop early mild onset diabetes, which recapitulate 
the GCK-MODY phenotype. These mice exhibit reduced islet glucokinase activity causing 
mildly elevated fasting blood glucose levels, and decreased glucose tolerance and abnormal 
liver glucose metabolism were observed during hyperglycemic clamp studies [14]. These 
rodent's studies further confirm that heterozygous inactivation of GCK gene would lead to 
deficiencies in both β cells and hepatocytes resulting in the hyperglycemia of MODY2. 
The known crystal structures of human GCK and its binding proteins [15, 16] reveal 
several critical functional domains which include glucose binding sites that form the 
active center of GCK and allosteric activator sites to which pharmacological GKAs bind [15], 
as well as glucokinase regulatory protein (GKRP) binding domains [16]. GKRP, acting as a 
competitive inhibitor with respect to glucose, regulates GCK activity and determines the 
subcellular location of glucokinase in liver [17]. When bound to substrates (glucose and 
ATP), glucokinase switches from a super-open inactive form to a closed active form 
catalyzing the production of G6P [15]. Therefore, introducing mutations into the closed 
active structure molecular model of glucokinase may help with the understanding of the 
abnormal biochemistry of different GCK mutations that result in altered GCK activity. 
 In order to gain further insight into the pathogenesis of GCK mutations, we have 
performed genetic screening of 96 Chinese MODY families for identifying possible 
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additional novel GCK mutations. Then using an integrated approach i.e. pedigree, molecular 
modeling, enzymology, GKRP inhibition and clinical profiling, we conducted the structure – 
function characteristics investigation of these naturally occurring GCK mutations. To address 
the concern for necessity treatment of hyperglycemia in MODY2, we also carried out a 
pharmacogenomics study to investigate the effect of glycaemic control with or without 
anti-diabetic pharmacological treatment in MODY2 patients.   
 
2.    Materials and Methods 
2.1.   Subjects  
Medical and family history questionnaires were completed by all participants, whose 
information was supplemented with information from the medical records. The American 
Diabetes Association criteria (2013) were used to diagnose diabetes, impaired fasting glucose 
(IFG), and impaired glucose tolerance (IGT). Written informed consent was obtained from all 
participants. This study was approved by the Shanghai Jiaotong University Affiliated Sixth 
People’s Hospital Institutional Review Board.   
96 MODY families included 424 affected subjects, wherein 96 MODY probands who 
fulfilled the classical MODY criteria (non-obesity, absence of autoantibodies, at least one 
patient with onset age <25 years, and a family history of diabetes for at least three 
consecutive generations) [18], but had mostly been misdiagnosed and mistreated as type 1 or 
type 2 diabetes by local hospitals, and their family members from 2014 to 2016, were 
referred to or recruited by the Shanghai Diabetes Institute, Department of Endocrinology & 
Metabolism, Shanghai Jiaotong University Affiliated Sixth People’s Hospital for GCK 
genetic testing, counselling and standardized clinical and laboratory evaluation [19]. 
Additionally, we enrolled unrelated 200 non-diabetic individuals, 118 male and 82 females, 
age, 66.3±2.7 years with the following criteria: age>60 years; body mass index (BMI), 
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22.0±0.7kg/m2, normal glucose tolerance, glycated haemoglobin (HbA1c) <5.6% (38 
mmol/mol), and no family history of diabetes. 
2.2.   Identification of GCK mutations 
The genomic DNA of the 96 MODY pedigrees was isolated from peripheral blood and used 
for screening GCK mutations by PCR–direct sequencing and multiplex ligation-dependent 
probe amplification (MLPA). Twelve exons of the human GCK expressed in pancreatic 
β-cells and hepatocytes (GenBank accession no.AH005826) were screened using previously 
described primer sequences [20]. The identified mutations were then tested for co-segregation 
with hyperglycaemia (diabetes, IFG or IGT) in other family members and the 200 
non-diabetic controls of Han Chinese origin. The mutations and variants were numbered 
according to the Human Genome Variation Society http:// www.hgvs.org/. 
2.3.   Construction of human glucokinase molecular model  
The crystal structure of human glucokinase has been determined by Kamata et al [15]. GCK 
mutants were constructed according to the active holo closed conformation (3VEY: 
ATP+GCK activator+glucose, Protein ata Bank database, http://www.rcsb.org/ pdb/explore. 
do?structureId=3VEY PubMed: 22298776). The mutations were analysed at the structural 
level by introducing the modifications into the 3VEY structure model. In addition, deleterious 
mutations were predicted using online prediction programs SIFT, PolyPhen-2, LRT, 
MutationTaster, FATHMM, and RadialSVM. 
2.4.   Production of recombinant GCK, and kinetic analysis and thermostability assays 
His-tagged wild-type (WT) and GCK mutants (mGCKs), generated by the QuikChange 
Site-Directed Mutagenesis Kit and the appropriate primers (Supplemental Table 1) were 
inserted into the expression vector pET28a to express the recombinant GCK proteins. The 
GCK proteins were expressed in Escherichia coli Rosetta 2 (DE3) pLysS, purified and stored 
as described previously [21, 22]. GCK activity was measured spectrophotometrically using a 
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SynergyTM4 multimode microplate reader (BioTek, Vermont, USA) by quantifying NADPH, 
which is directly proportional to the concentration of glucose-6-phosphate (G6P) generated 
by GCK. The kinetic parameters of WT GCK and its mutants were measured and calculated 
using Sigmaplot 13.0 (Systat Software, San Jose, USA). The relative activity index and 
glucose concentration at the inflection point were calculated as previously described [21]. 
The thermal stability of GCKs was determined as described previously [22]. Eight proteins 
were pre-incubated at various temperatures, i.e., 35°C, 40°C, 45°C, 50°C, 55°C, 60°C and 
65°C for 30 min in a reaction buffer without substrates, then ATP (5 mM) and glucose (200 
mM) were added to the reaction mixtures and incubated for 10 min at 37°C; the product G6P 
was quantified. The G6P yields of inactivated enzymes were divided by that of unheated 
inactivated enzymes and used as the remaining relative activity. Furthermore, the 
heat-inactivation curves at 52.5°C were determined for wild type of GCK and its mutants. 
2.5.   Yeast two-hybrid (Y2H) system 
mGCK-encoding cDNAs were inserted into pGBKT7 vector (Clontech) using KpnI and 
BamHI to generate pGBKT7-mGCK, and then transformed into Saccharomyces cerevisiae 
strain Y2HGold as the bait. WT GCK was used as the positive control. GKRP-encoding 
cDNA was cloned into pGADT7 vector (Clontech) using KpnI and BamHI to generate 
pGADT7-GKRP, and then S. cerevisiae strain Y187 was transformed with the constructs as 
the prey. Diploid S. cerevisiae strains were obtained using small-scale transformation, and 
then plated on SD/-Leu/-Trp Agar, SD/-Leu/-Trp/(DDO), and SD/-Ade/-His/-Leu/-Trp/ 
X-a-Gal/AbA (QDO/X/A) agar plates; the activity of the secreted α-galactosidase was 
subsequently measured according to Matchmaker Gold Y2H System user manual [23]. 
2.6.   Pharmacogenomics study 
We compared HbA1c, age at diagnosis, and BMI in 38 MODY2 patients without insulin 
resistance (HOMA-IR<2) from ten MODY2 families, who were receiving oral 
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hypoglycaemic agents (OHA, n=17), insulin (n=12), or no treatment (n=9). The OHA-treated 
patients at referral received anti-diabetic drugs with low dose that equate to 500 mg 
metformin or 0.5 mg glimepiride per day. In the insulin-treated patients, the median insulin 
dose was 0.2 U/kg/day (range, 0.1–0.4 U/kg/day). 
2.7.   Statistical analysis 
All clinical and laboratory values are presented as means ± SEM or as medians (interquartile 
range) unless otherwise stated. Comparisons of the clinical and laboratory parameters 
between or among groups were performed using unpaired Student’s t-tests, where data with 
skewed distribution were logarithmically transformed before analysis, or one-way ANOVA 
and Pearson χ2 tests as appropriate. P<0.05 was considered to be significant. SPSS19.0 
(SPSS Inc.) was used for data analysis and processing. 
 
3.    Results 
3.1.   Genetic and clinical characteristics  
Ten GCK mutations were identified in ten unrelated MODY families, including five novel 
(F195S, I211T, V222D, E236G and K458R) and five previously reported mutations (T49N, 
I159V, R186X, A188T and M381T [4, 5, 24-26] (Fig. 1, Supplemental Fig. 1, Supplemental 
Table 2). The sequences were found to be evolutionally well-conserved across different 
mammal species, except that I159 was substituted with L159 in the rat, and these mutations 
were co-segregated with hyperglycaemia (diabetes, IGT, or IFG) in their respective pedigrees 
(Fig. 1). GCK mutations were not identified in the other probands or the 200 controls, 
suggesting that these mutations are not simple polymorphisms.  
In the ten pedigrees, MODY2 subjects (n=55) had significantly elevated fasting plasma 
glucose (FPG), 2-h postprandial plasma glucose (2hPG) and HbA1c，decreased fasting 
insulin (FINS)/FPG and 2-h insulin (2hINS)/2hPG, compared to their unaffected relatives 
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(n=36) (all, p<0.001, Table 1). It was noteworthy that 31% (n=17) of MODY2 patients 
showed signs of insulin resistance with homeostatic assessment of insulin resistance 
(HOMA-IR) index ≥2.0，the HbA1c of which was significantly higher than those without 
insulin resistance（6.7±0.3 vs 6.4±0.2，p=0.038, Supplemental Table 3). The onset age and 
BMI in the former were also higher respectively than that in the latter, although no significant 
differences were observed (both p>0.05, Supplemental Table 3). None of these patients had 
any chronic diabetic complications. 
3.2.   mGCK model construction  
To investigate whether the conformational alterations caused by mutations contribute to the 
change of protein function, mGCK molecular models were constructed. As shown in Fig. 2a, 
the location of the ten GCK mutations was modelled on the global landscape of the GCK 
protein structure. Then, the mutations were studied at the structural level by introducing the 
modifications into the 3VEY structure model (Fig. 2b-k). The V222D, E236G, and R186X 
mutations were predicted to result in the most serious damage to the spatial conformation 
(Fig. 2b-d). V222D – Valine 222 formed a large hydrophobic core of the large domain with 
the side chains of M224, A232, Y234, L386, V389, I390, M393, I404 and V406 residues (Fig. 
2b). A negative-charge polar hydrophilic D222 residue replaced a non-polar hydrophobic 
V222 residue, severely destroying the stability of the hydrophobic core in the large domain. 
E236G – A non-polar hydrophobic and uncharged Glycine 236 substituted a negative-charge 
polar hydrophilic residue E236, causing the loss of the salt bridge–hydrogen bond network 
formed by E236 with Y234, E237, N240, and R392 (Fig. 2c). R186X - The R186X mutation 
generated a truncated protein lacking 280 amino acids, as only two glucose binding sites, i.e., 
Thr168 and Lys169 in the small domain were reserved (Fig. 2d); it could not bind to glucose 
and catalyse the reaction from glucose and ATP to G6P.  
However, the other seven mutations i.e., T49N, I159V, A188T, F195S, I211T, M381T 
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and K458R resulted in different degrees of GCK instability through a change in the 
three-dimensional (3D) structure (Fig. 2e-k), thus leading to decreased enzyme activity. 
T49N - N49 formed a pair of new hydrogen bonds with the side chains of E48, but lost the 
hydrogen bond with R43 (Fig. 2e). I159V - I159V mutation resulted in shorter side chains, 
thereby weakening the hydrophobic interaction with surrounding residues (Fig. 2f). A188T 
-The CH3 group on the side chain of T188 embedded deeply inside may form a larger steric 
hindrance with surrounding residues (Fig. 2g). F195S - F195S mutation impairs local 
hydrophobic interaction formed with I130, L134, I189 and M197 (Fig. 2h). I211T - The 
I211T, a mutation located on allosteric activator site, reduces the hydrophobic interaction and 
encapsulates the OH groups of the T-side chains in the interior to form unsaturated hydrogen 
bonds with large dewatering free energy (Fig. 2i). M381T -The side chain OH groups of 
T381 forms hydrogen bonds with the main chain carbonyl O of R377, but it is difficult to 
offset the unfavorable dewatering free energy (Fig. 2j). K458R - K458 substituted by R458 
may not affect the distribution of the surrounding charge and the solubility of protein due to 
the similar physical and chemical properties (Fig. 2k). Moreover, at least five of the six 
online prediction tools predicted that these ten mutations were deleterious (Supplemental 
Table 4) (24). 
3.3   mGCK kinetic analysis and thermostability 
To investigate how the GCK mutations affect GCK protein’s function, we analysed GCK 
catalytic activity. Recombinant proteins of mGCK were expressed and purified (Fig. 3a), 
GCK activity and thermostability were determined. The activity of V222D, E236G and 
R186X were too low to generate clear products in the presence of 1 mg/mL protein, 
indicating that three mutations are almost completely inactive (Fig. 3b). All other mutations 
affect GCK activity with different severities. The GCK activities of these mutants compared 
to wild type GCK were decreased in the order of WT>M381T> K458R>I211T> 
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I159V>F195S>T49N>A188T (Fig. 3b), which is consistent with their catalytic efficiency for 
glucose (Kcat/S0.5) (Table 2).  Thermostability is a critical criterion of protein which can be 
used to evaluate protein structure stability. Compared with WT GCK, all seven mGCKs 
shows decreased thermostability, especially M381T. The GCK thermostabilities were in the 
order of WT>I159V> K458R>F195S>A188T>I211T>T49N>M381T. All mGCKs lost >50% 
activity at 49°C, the temperature at which WT GCK lost 50% activity (Fig. 3c). Compared 
with the half-life of WT (7.2 min) at 52.5°C, the mGCKs have shorter ones (Fig. 3d). All 
seven mutants exhibit reduced GCK activities and thermostability. It is noteworthy that 
V222D, E236G and R186X three mutants are completely inactive and dynamic parameters 
and thermostability analysis of them was not applicable.  
3.4.   GCK mutations altered interactions with GKRP 
Since GCK is also regulated through protein-protein interactions by the glucokinase 
regulatory protein (GKRP), which inhibits the enzyme and also induces its nuclear retention 
in hepatocytes, we investigated that whether these mutation of GCK affect interaction of 
mGCKs with GKRP using yeast two hybrid (Y2H) system. As showed in Fig. 4, the 
interaction strength was quantitatively determined via assaying the α-galactosidase activity, in 
comparison to WT GCK, the I211T, I159V, T49N and K458R mutations exhibited enhanced 
inhibition by GKRP, while F195S and M381T showed decreased interactions with GKRP as 
reflected by the activity of α-galactosidase (p<0.05 or p<0.001), in which the I211T revealed 
the strongest inhibition (Fig. 4). However, the activity of α-galactosidase expressed by the 
reporter gene GLA was not detected from the S. cerevisiae expressing the A188T (Fig. 4) and 
R186X mutants (data not shown). Yeast auxotrophic selection confirmed this result, as the 
diploid S. cerevisiae strain expressing the A188T mutant and GKRP could not survive under 
this condition (data not shown).  
3.5.   Pharmacological treatment did not affect HbA1c in MODY2 patients without 
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insulin resistance  
To assess whether patients with MODY2 need hypoglycaemic therapy, the effects of 
pharmacological treatment and the absence thereof on their glycaemic control were evaluated. 
Of the 38 MODY2 patients without insulin resistance, there was no significant difference in 
HbA1c between patients on pharmacological therapy (n=29) and those without (n=9): 
OHA+insulin vs. no treatment: 6.4±0.1 vs. 6.3±0.3 (p=0.618, Fig. 5), indicating 
pharmacological treatment for these patients did not alter glycaemic control. The patients on 
OHA treatment were older at onset age than the patients on insulin or without medication: 
OHA vs. insulin vs. no treatment, 24 (21.5, 34.0) vs. 14.5(2.6, 28.0) vs. 12 (2.2, 24.0) years 
(p=0.005).  
 
4.    Discussion  
GCK phosphorylates glucose to G6P and plays a major role in regulating glucose metabolism 
in pancreatic β-cells and hepatocytes [1]. The glucokinase gene consists of 12 exons and 
encodes a 465-amino-acid protein [27] with three tissue-specific isoforms due to alternative 
splicing at exon 1 [28]. The ten GCK mutations identified in this study are localized to exons 
2–10, which are common exons for both the pancreatic and hepatic GCK isoforms. Therefore, 
these mutations would cause GCK dysfunctions in both cell types and result in fasting and 
postprandial hyperglycaemia in these MODY2 patients (Table 1). Decreased FINS/FPG and 
2hINS/2hPG in MODY2 patients (Table 1) demonstrate the defects in insulin secretion and 
agree with the observation in Caucasians and Japanese MODY2 patients as reported 
previously [4, 12]. Interestingly, 31% (17/55) of MODY2 patients showed signs of insulin 
resistance (HOMA-IR≥2) in this study, which was also seen in 25% of Japanese MODY2 
patients [12], demonstrating that familial insulin resistance is more common in Asian people 
[29, 30]. Nevertheless, despite the uneven enzyme activity exhibited in these ten GCK 
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mutants (Table 2), no differences in MODY2 phenotypes were observed, thus we cannot 
establish a clear relationship between the severity of the biochemical defect and the actual 
diagnosis and treatment. These data support the hypothesis that similar phenotype of 
MODY2 patients resulting from heterozygous mutations in GCK could be explained by the 
fact that one adapted wild-type allele could compensate for the enzyme defects caused by the 
mutant allele [21].  
4.1.   Both complete and partial inactivation of GCK led to MODY2 
Ten mutations were identified in 96 MODY pedigrees in mainland China, five of which 
are reported for the first time (F195S, I211T, V222D, E236G and K458R). We found close 
association between structural alterations of these mutants predicted by molecular modeling 
and their enzyme activities. Based on the GCK enzymatic activity, the identified mutations 
can be classified into two main categories: completely inactive mutations (V222D, E236G 
and R186X) and partially inactive mutations (T49N, I159V, F195S, I211T, M381T, K458R 
and A188T).  
R186X mutation generates a truncated form shorter than E440X that cuts the only vital 
C-terminal end of the GCK peptide and inactivates the cytoplasmic enzymatic activity of the 
protein [31], thus R186X was predicted to be a completed loss of function of GCK. As 
expected, we observed that R186X mutant does not have any GCK enzymatic activity. 
V222D mutation introduces a net negative charge into a hydrophobic environment, which 
destroyed the large hydrophobic core formed with surrounding nine residues in the large 
domain (Fig. 2b). E236G mutation disrupted the perfect salt bridge hydrogen bond network 
formed with Y234, E237, N240 and R392 residues (Fig. 2c). V222D and E236G caused 
nearly complete loss of enzyme activity, similar to R186X which lost four glucose binding 
sites of GCK (Fig. 2d, Fig. 3b). Similarly, Gly162Asp introduced a net negative charge into a 
hydrophobic core [32] and Arg392Ser destroyed the salt bridge bond [33], which have been 
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reported to lead to the development of MODY2. Therefore, the associated kinetic parameters 
and thermo-stabilities of V222D and E236G could not be accurately determined due to the 
full loss of enzyme activity, similar to that of R186X (Table 2). Although R186X was 
reported to be a mutation resulting in a truncated protein, no known studies have thoroughly 
analysed the structure and the G-6-P generation activity of this fully inactivated protein 
previously.  
Enzymatic activity studies indicate that partial inactive mutations (I211T, I159V, T49N, 
K458R, F195S, M381T and A188T) exhibited a reduction in relative activity index and 
protein instability (Table 2, Fig. 3c, 3d). Notably, the interaction with GKRP was 
significantly enhanced for the four mutants (I211T, I159V, T49N and K458R), decreased in 
F195S and M381T, and totally lost with A188T (Fig. 4) compared to that of the wild-type 
(p<0.05 or p<0.001). Among them, M381T shows the mildest decrease in catalytic efficiency 
(Kcat1/S0.5) and the strongest effect on protein thermo-stability (Table 2, Fig. 3c, 3d), while 
A188T has the lowest enzyme activity and lost the interaction with GKRP (Table 2, Fig. 4). 
Enhanced GKRP inhibition for the four mutations may be the result of an increase in the 
binding affinity between the super-open form of GCK and GKRP, which may further 
decrease enzymatic activity and cause mis-localization of the protein. In addition, decreased 
or lost interactions between GKRP and F195S, M381T or A188T may mean that defects in 
the regulation of GCK by GKRP lead to catalytic instability [34] or hepatic nuclear reserves 
of these mutant enzymes were markedly reduced [35], which consequently hinders the 
clearance of postprandial glucose by the liver, thus contributing to the hyperglycemia in this 
MODY patients. The lack of GKRP inhibition of A188T may be explained by the fact that 
A188 is adjacent to R186 which reinforce the hydrophobic contact between the small domain 
residues of GCK and GKRP [16], while A188 is spatially close to His-141 to Leu-144, the 
binding sites of GCK with GKRP [36], the mutational T188 may change the 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
15 
 
spatial conformation , prevents R186 function and/or covers the GKRP binding site. However, 
the mechanism of how mutations affect the interaction between GCK and GKRP will be 
confirmed with crystal structure analysis of the mutational GCK-GKRP complex and the 
hepatocyte localization experiment in vitro. Thus, these findings may offer new evidence to 
support the notion that the disturbance of GCK-GKRP may be account for some of MODY2 
underlying mechanism for postprandial hyperglycaemia (Table 1) resulting from decreased 
hepatic glycogen accumulation and augmented hepatic gluconeogenesis observed in 
glucokinase-deficient patients [37]. 
4.2.   Possible alternative strategy for MODY2  
Our study found that 69% (38/55) of MODY2 patients showed no insulin resistance, 
wherein there was no difference in HbA1c in the patients on pharmacological regimes (n = 29) 
and those without (n = 9) (Fig.5). Therefore, our results provided an evidence for MODY2 
patients who do not require hypoglycaemic therapy [6], however, no-treatment should only 
be limited to those patients without insulin resistance. The lack of response to routine 
hypoglycaemic medicine (insulin or OHA) may support a possibility i.e. the presence of a 
glucose sensing defect in patients with MODY2 results in a glucose level that is regulated at 
its raised level [38]. Thus, MODY2 patients and their family members could halt their 
conventional anti-diabetic treatment to avoid medication adverse effects, which represents a 
special example of pharmacogenomics in hypoglycaemic therapy.  
The HbA1c levels of patients with insulin resistance were significantly elevated as 
compared with those of patients without insulin resistance（6.7±0.3 vs 6.4±0.2，p=0.038, 
Supplemental Table 3）. Therefore, these patients should be treated with OHA such as 
metformin to improve their insulin sensitivity. Our results demonstrated a new insight that 
patients with MODY2 without insulin resistance do not require hypoglycaemic therapy. In 
addition, despite mild hyperglycaemia, the elevation of HbA1c and the generation of 
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advanced glycation end products (AGE) that induces various deleterious biological effects 
[39] may be responsible for the development of diabetic microvascular complication in 4-6% 
of MODY2 patients [4]. Therefore, it is essential to develop new hypoglycaemic drugs with 
GKA and GCK-GKRP disruptor targeting to elevate GCK activity, while single or 
combined application of them may be expected to improve hyperglycaemia of MODY2 
patients. 
4.3.   Misdiagnosis of MODY2   
In addition, the patients on OHA treatment were older at onset age than the patients on 
insulin or without medication: 24 (21.5, 34.0) vs. 14.5(2.6, 28.0) vs. 12 (2.2, 24.0) years 
(p=0.005), suggesting that the onset in children or adolescents were usually misdiagnosed as 
type 1 diabetes, thus insulin was prescribed; those with onset in later life were easily 
misdiagnosed as type 2 diabetes, and were treated with OHAs. Our results suggested that, 
without genetic diagnosis, the clinical misdiagnosis rate of MODY2 was 85.4% (47/55) in 
China; moreover, 58.2% (32/55) of MODY2 patients received incorrect treatment. Similarly, 
the US SEARCH for Diabetes in the Youth study reported that most MODY cases were 
misdiagnosed as type 1 (36%) or type 2 diabetes (51%), wherein 100% of MODY2 patients 
were clinically misdiagnosed and 50% were receiving the wrong treatment [40]. The key 
driver for precision diabetes is that genetic aetiology strongly influences treatment choice and 
the clinical course [19, 41]. Therefore, genetic diagnose of MODY and differentiating 
MODY from type 1 and type 2 diabetes is crucial to enable the correct classification of 
diabetes and precise individual treatment. 
4.4.   Estimated more than 1.2 million MODY patients in China 
The most recent diabetes epidemiology study in China in 2017 reported that the estimated 
overall prevalence of diabetes and pre-diabetes was 10.9% and 35.7%, or 119 million and 388 
million individuals, respectively [42]. In case that MODY constitutes 1–5% of diabetes cases 
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[18], there may be at least 1.2 to 6.0 million MODY patients in China, which is around 
100-fold of the number of British Caucasian MODY patients (26,000) [9]. GCK-MODY may 
be one of the two frequent subtypes among the 13 MODY subtypes discovered in the Chinese 
population so far   [7, 13, 19, 43, 44], which is supported by this study that observed a 
10.4% frequency of MODY2 occurrence (10 out of 96 families). Implementation of genetic 
testing of MODY2 and personalization of their hypoglycaemic medication may have great 
benefit to these MODY2 patients. 
One of interesting findings of the present study is that MODY2 occurrence frequency is 
much higher than previously reported. According to conventional MODY criteria [18], 96 
MODY probands and their family members who had been misdiagnosed as type 1 or type 2 
diabetes were recruited. Among them, 10 GCK mutations, i.e., 10.4% frequency of MODY2 
were observed. This is much higher than the rate of GCK mutation (1%) found in the Hong 
Kong study using minimum MODY criteria [7]. However, the present study also had some 
limitations. The result of this cross-sectional study indicates that MODY2 patients without 
insulin resistance should not be prescribed any treatment, however no follow-up study has 
been performed to confirm this. Therefore, a drug withdrawal follow-up study combining 
genetic tests with a larger number of patients should be conducted. Furthermore, to 
investigate the more accurate mutation spectrum and prevalence of MODY2 among Chinese 
patients with MODY, additional studies should expand the number of MODY pedigrees. 
In summary, five new and five known mutations of GCK were identified from 96 
MODY pedigrees. Structural alteration of these mutations led to defects in enzymatic activity 
and protein stability. Together with the abnormality of GKRP regulations on GCK mutants, 
these alterations may synergistically result in the development of hyperglycaemia of MODY2 
in Chinese. This study proposes that MODY2 patients and their family members without 
insulin resistance could halt their conventional anti-diabetic treatment to avoid unnecessary 
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medication adverse effects. Since MODY2 patients without insulin resistance lack response 
to conventional hypoglycaemic agents, the development and use of new medication targeting 
to increased GCK activity, i.e. GKA and/or GCK-GKRP disruptors, could be a possible new 
therapeutic approach to treat MODY2 patients. 
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Table legends 
Table 1: Clinical and biochemical parameters of ten MODY2 family members 
Data are the means±SEM, medians (interquartile range), or n (%).  
a GCK mutation-negative, normal glucose tolerance first-degree relatives. 
M=male; BMI=body mass index; FPG=fasting plasma glucose; 2hPG=2-h postprandial 
plasma glucose; FINS=fasting plasma insulin; 2hINS=2-h postprandial plasma insulin. 
Table 2: Kinetic parameters of WT and mGCKs 
As the activity of V222D, E236G, and R186X were so low such that they did generate clear 
products in the presence of 1 mg/mL protein, the calculating dynamics parameters could not 
be calculated. Data are the means±SEM of three separate enzyme expressions. h=Hill 
coefficient; kcat=GCK catalytic constant; S0.5=affinity constant for glucose; Km=affinity 
constant for ATP; nd=not detected. vs. wild-type, ***p<0.001, **p<0.01, *p<0.05. 
 
Figure legends 
Figure 1: Pedigrees, genotypes, and clinical characteristics of ten MODY2 families  
(a-j): Ten family trees: black circles and squares, participants diagnosed with MODY2; 
half-filled black circles and squares, IGT or IFG; white circles and squares, normal glucose 
tolerance (NGT); red arrows, probands for the ten families. Numbers under the symbols are 
the family members’ identification numbers, followed by the genotype of mutation, then age 
at diagnosis of diabetes and age at examination, followed by treatment for diabetes before 
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genetic diagnosis. nd=not detected; OHA=oral hypoglycaemic agents; N=normal allele; 
m=mutant allele.  
Figure 2: Model construction and free energy calculation of WT and mGCKs 
(a) Location of ten mutations in the 3D model of human β-cell GCK. The GCK structure in  
the active closed form (3VEY) is shown: purple, small domain; blue, large domains; grey, 
connecting region; yellow spheres, glucose; multi-colored chain, ATP. Six glucose binding 
sites, i.e., T168, K169, E256, E290, N204, and D205, are marked with red in the GCK 
molecular chain. Deep pink or yellow chains, mutation sites. (b–k) Effects of the ten 
mutations on the GCK structure model. Green spheres, WT GCK; red spheres, mGCKs. 
Interacting residues that formed the hydrophobic cores with WT residues at the mutated sites 
are marked in deep yellow in the GCK molecular chain. Yellow spheres, glucose; 
multi-colored chain, ATP.  
 
Figure 3: Purification, activity, and thermostability of mGCKs 
(a) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of purified WT  
GCK and mGCK proteins. Proteins (2 μg per lane) were loaded onto 15% SDS-PAGE to 
confirm their purity. (b) Comparison of mGCK activity. The G6P yield was analysed under 
different enzyme concentrations (n=3). (c) Remaining mGCK activity after incubation at 
different temperature. (d) Time course of GCK heat inactivation at 52.5°C.  
Figure 4: Y2H quantification of the interaction between mGCK and GKRP 
Quantification of secreted α-galactosidase activity from the culture supernatant of Y2H Gold 
yeast colonies expressing mGCK and human GKRP. Bars and error bars, means±SEM. 
*p<0.05, ***p<0.001.  
Figure 5: Comparison of HbA1c levels among MODY2 patients with or without 
pharmaceutical treatment in a cross-sectional study 
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HbA1c levels of MODY2 patients treated with OHAs (n=17), insulin (n=12), or no treatment 
(n=9) before genetic testing. Bars and error bars, means±SEM. 
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Table 1: Clinical and biochemical parameters of ten MODY2 family members 
 
 
Data are the means±SEM, medians (interquartile range), or n (%).  
a GCK mutation-negative, normal glucose tolerance first-degree relatives. 
M=male; BMI=body mass index; FPG=fasting plasma glucose; 2hPG=2-h postprandial plasma glucose; 
FINS=fasting plasma insulin; 2hINS=2-h postprandial plasma insulin. 
 
 
 MODY2 patients (n=55) 
Unaffected relatives a 
(n=36) p-value 
Sex (M) 34 (61.8%) 16 (44.4%) 0.133 
Age (years) 35.0（12.0, 60.0） 37.5（30.1, 57.8） 0.491 
Age at diagnosis of diabetes (years) 23.0（12.0, 30.0） -  
Diabetes duration (years) 14.0（2.5, 27.0） -  
BMI (kg/m2) 21.3±2.5 22.1±1.9 0.391 
HbA1c (%) 6.5±0.2  5.1±0.1 < 0.001 
FPG (mmol/L) 7.2±0.3   4.7±0.2 < 0.001 
2hPG (mmol/L) 10.0±0.8    5.8±0.4 < 0.001 
FINS (mU/L) 4.7 (2.9, 6.9) 5.3（4.6, 6.0） 0.107 
2hINS (mU/L) 22.9 (14.2, 35.3)   30.0（25.1, 37.2） 0.188 
FINS/FPG (mU/mmol) 0.7 (0.4, 1.0) 1.2（1.0, 1.3） < 0.001 
2hINS/2hPG (mU/mmol) 2.4 (1.4, 3.7)  4.9（4.2, 6.8） < 0.001 
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Table 2: Kinetic parameters of WT and mGCKs 
Muta
tion 
Yield 
(mg/l) 
S0.5 
(mM) 
Hill 
coeffici
ent 
(h) 
Inflectio
n 
point 
(mM) 
ATP, 
Km 
(mM) 
Glucos
e, kcat1 
(s-1) 
ATP, 
kcat2 (s-1) 
Activit
y 
index 
Rela
tive 
activ
ity 
inde
x 
kcat1/S0
.5 
(s-1/m
M) 
WT 
24.97±0.
11 
7.67±0.1
6 
1.75±0.
04 
3.65±0.1
9 
0.50±0.
01 
11.47±0
.67 
16.96±0.
18 
0.26±0.
04 
1.00 
1.50±0.
12 
V222
D 
6.90±0.0
5***  
nd nd nd nd nd nd nd nd nd 
E236
G 
16.30±0.
10*** 
nd nd nd nd nd nd nd nd nd 
R186
X 
20.03±0.
11***  
nd nd nd nd nd nd nd nd nd 
T49N 
21.0±0.1
3***  
31.13±0.
70*** 
1.58±0.
06 
11.96±0.
73*** 
0.44±0.
00*** 
4.48±0.
16*** 
15.48±0.
05*** 
0.02±0.
00*** 
0.08 
0.14±0.
01*** 
I159V 
22.1±0.1
5*** 
35.85±1.
39*** 
1.37±0.
01*** 
9.18±0.4
1*** 
0.50±0.
01 
10.31±
0.28 
13.84±0.
16*** 
0.06±0.
01** 
0.23 
0.29±0.
01*** 
F195
S 
21.57±0.
11***  
20.04±0.
58*** 
1.78±0.
01 
9.81±0.2
6*** 
0.63±0.
01*** 
4.50±0.
05*** 
13.71±0.
13*** 
0.02±0.
00*** 
0.08 
0.22±0.
01*** 
I211T 
22.4±0.0
8**  
13.94±0.
14*** 
1.56±0.
04* 
5.20±0.2
9* 
0.40±0.
01*** 
8.98±0.
35* 
10.34±0.
12*** 
0.13±0.
02* 
0.5 
0.64±0.
02*** 
M381
T 
24.13±0.
13  
11.20±0.
43** 
1.64±0.
04 
4.72±0.1
3** 
0.49±0.
01 
11.52±0
.21 
16.36±0.
11* 
0.18±0.
01* 
0.69 
1.03±0.
03** 
K458
R 
23.6±0.0
8**  
11.02±0.
05*** 
1.82±0.
01* 
5.61±0.0
6*** 
0.61±0.
01** 
10.77±
0.08 
16.01±0.
18* 
0.10±0.
01** 
0.38 
0.98±0.
01** 
A188
T 
23.17±0.
11*** 
51.70±0.
48*** 
1.34±0.
02*** 
12.40±0.
56*** 
0.35±0.
00*** 
3.17±0.
09*** 
12.43±0.
06*** 
0.01±0.
00*** 
0.04 
0.06±0.
00*** 
As the activity of V222D, E236G, and R186X were so low such that they did generate clear products in the 
presence of 1 mg/mL protein, the calculating dynamics parameters could not be calculated. Data are the 
means±SEM of three separate enzyme expressions. h=Hill coefficient; kcat=GCK catalytic constant; 
S0.5=affinity constant for glucose; Km=affinity constant for ATP; nd=not detected. vs. wild-type, ***p<0.001, 
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**p<0.01, *p<0.05. 
 
 
 Highlights  
1) Five novel and five known mutations were identified in MODY pedigrees.  
2) MODY2 accounts for 10.4% of classical MODY cases in Chinese in this study.  
3) Defects in enzymatic activity, stability and GKRP interaction may co-induce MODY2.  
4) 31% of MODY2 patients showed signs of insulin resistance  
5) No treatment should be prescribed to MODY2 patients without insulin resistance.  
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